title: A Phase II Study of the Combination of Bevacizumab, Pertuzumab, and Octreotide LAR for Patients with Advanced Neuroendocrine Cancers.
abstract: OBJECTIVE
  To evaluate efficacy and safety of bevacizumab, pertuzumab, and octreotide depot for advanced neuroendocrine tumors.
  
  
  METHODS
  Patients received bevacizumab 15 mg/kg and pertuzumab 420 mg IV q21 days with octreotide depot 30 mg IM q28 days.
  
  
  RESULTS
  Toxicities in 43 patients included diarrhea (63%), fatigue (63%), hypertension (44%), and nausea (44%). Reversible G3 hypertension (26%) and LVEF decline (9%) occurred. 7/43 patients achieved objective response (typical carcinoid, 5; pancreatic NET, 2). Median PFS and OS were 6.5 and 26.4 months, respectively.
  
  
  CONCLUSIONS
  Bevacizumab, pertuzumab, and octreotide depot was well-tolerated with a 16% ORR. Results in the well-differentiated carcinoid tumors are thought provoking.
authors.affiliation: a Sarah Cannon Research Institute , Nashville , TN , USA.|b Tennessee Oncology, PLLC , Nashville , TN , USA.
authors.forename: Johanna C
authors.initials: JC
authors.lastname: Bendell
authors.affiliation: c Florida Hospital Cancer Institute , Orlando , FL , USA.
authors.forename: Ahmed
authors.initials: A
authors.lastname: Zakari
authors.affiliation: a Sarah Cannon Research Institute , Nashville , TN , USA.|d OHC (Oncology Hematology Care) , Cincinnati , OH , USA.
authors.forename: Evan
authors.initials: E
authors.lastname: Lang
authors.affiliation: a Sarah Cannon Research Institute , Nashville , TN , USA.|d OHC (Oncology Hematology Care) , Cincinnati , OH , USA.
authors.forename: David
authors.initials: D
authors.lastname: Waterhouse
authors.affiliation: a Sarah Cannon Research Institute , Nashville , TN , USA.|d OHC (Oncology Hematology Care) , Cincinnati , OH , USA.
authors.forename: Douglas
authors.initials: D
authors.lastname: Flora
authors.affiliation: e Grand Rapids Oncology Program , Grand Rapids , MI , USA.
authors.forename: Kathryn
authors.initials: K
authors.lastname: Alguire
authors.affiliation: a Sarah Cannon Research Institute , Nashville , TN , USA.|f Florida Cancer Specialists , Ft. Myers , FL , USA.
authors.forename: Michael
authors.initials: M
authors.lastname: McCleod
authors.affiliation: a Sarah Cannon Research Institute , Nashville , TN , USA.|b Tennessee Oncology, PLLC , Nashville , TN , USA.
authors.forename: Nancy
authors.initials: N
authors.lastname: Peacock
authors.affiliation: a Sarah Cannon Research Institute , Nashville , TN , USA.|d OHC (Oncology Hematology Care) , Cincinnati , OH , USA.
authors.forename: Peter
authors.initials: P
authors.lastname: Ruehlman
authors.affiliation: a Sarah Cannon Research Institute , Nashville , TN , USA.
authors.forename: Cassie M
authors.initials: CM
authors.lastname: Lane
authors.affiliation: a Sarah Cannon Research Institute , Nashville , TN , USA.
authors.forename: Chris
authors.initials: C
authors.lastname: Earwood
authors.affiliation: a Sarah Cannon Research Institute , Nashville , TN , USA.|b Tennessee Oncology, PLLC , Nashville , TN , USA.
authors.forename: Kent
authors.initials: K
authors.lastname: Shih
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D018358:Neuroendocrine Tumors / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D015282:Octreotide / Q000008:administration & dosage; D019233:Retreatment; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; C485206:pertuzumab; D015282:Octreotide
keywords: Angiogenesis; Monoclonal antibodies; Pancreatic cancer